바로가기: 본문 바로가기; 메인메뉴 바로가기

CGRL: Cancer Genomics
Research Laboratory

Publications

Translational Research

Home > PUBLICATIONS > Translational Research

No.	Journal	File
67	Yun J, Song SH, Kim HP, Han SW, Yi EC,Kim TY Dynamic cohesin-mediated chromatinarchitecture controls epithelial-mesenchymal plasticity in cancer. EMBO Rep. 2016 Jul 27.
66	Yun J, Song SH, Kang JY, Park J, Kim HP, Han SW, Kim TY., Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability., Nucleic Acid Research 2015 Sep 29. [Epub ahead of print]
65	Jeon MS, Song SH, Yun J, Kang JY, Kim HP, Han SW, Kim TY, Aberrant Epigenetic Modifications of LPHN2 Function as a Potential Cisplatin-specific Biomarker for Human Gastrointestinal Cancer., Cancer Res Treat., 2015 Sep 22. [Epub ahead of print]
64	Kang JY, Song SH, Yun J, Jeon MS, Kim HP, Han SW, Kim TY., Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression., Oncogene., 2015 Feb 23. [Epub ahead of print]
63	Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ., Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells., Breast Cancer Res., 2015 Mar 7;17:33.
62	Kang JY, Song SH, Yun J, Jeon MS, Cha Y, Lee SH, Kim HP, Jeong EG, Han SW, Cho NY, Kook MC, Kang GH, Kim TY., Identification of long-range epigenetic silencing on chromosome 15q25 and its clinical implication in gastric cancer., Am J Pathol. 2015 Mar;185(3):666-78.
61	Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY., KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX., Ann Surg Oncol., 2015 Jan;22(1):187-94.
60	Kim HP, Cho GA, Han SW, Shin JY, Jeong EG, Song SH, Lee WC, Lee KH, Bang D, Seo JS, Kim JI, Kim TY., Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis., Oncogene., 2014 Nov 20;33(47):5434-41.
59	Cha Y, Han SW, Seol H, Oh DY, Im SA, Bang YJ, Park IA, Han W, Noh DY, Kim TY., Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer., Anticancer Res., 2014 Aug;34(8):4275-80
58	Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY., Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer., Oncogene. , 2014 Jun 19;33(25):3334-41.
57	Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Kim KY, Park SY,Lee DW, Won JK, Jeong SY, Park KJ, Park JG, Kang KH, Seo JS, Kim JI, Kim TY. , RNA editing in RHOQ promotes invasion potential in colorectal cancer., J Exp Med , 2014 Apr 7;211(4):613-21.
56	Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC., Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line., Exp Mol Med., 2013 Nov 22;45:e64.
55	Min A, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, Kim HP, Lee KH, Han SW, Oh DY, Kim TY, O Connor MJ, Kim WH, Bang YJ., RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib., Mol Cancer Ther., 2013 Jun;12(6):865-77.
54	Kang MJ, Kim HP, Lee KS, Yoo YD, Kwon YT, Kim KM, Kim TY, Yi EC., Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells., Proteomics. , 2013 May;13(10-11):1714-25.
53	Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY., Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing., PLoS One., 2013 May 21;8(5):e64271.
52	Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY., Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer., Int J Cancer., 2013 May 1;132(9):2209-16.
51	Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY., Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemotherapy and Pharmacology, 2013 Apr;71(4):843-51.
50	Park JH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kang GH, Chie EK, Ha SW, Jeong SY, Park KJ, Park JG, Kim TY., The beneficial effect of palliative resection in metastatic colorectal cancer., Br J Cancer., 2013 Apr 16;108(7):1425-31.
49	Nam HJ, Im SA, Oh DY, Elvin P, Kim HP, Yoon YK, Min AR, Song SH, Han SW, Kim TY, Bang YJ., Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents, in gastric cancer., Mol Cancer Ther., 2013 Jan;12(1):16-26.
48	Nam HJ, Kim HP, Yoon YK, Song SH, Min AR, Han SW, Im SA, Kim TY, Oh DY, Bang YJ., The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines., Invest New Drugs., 2012 Dec;30(6):2148-60.

이전페이지

1 2 3 4 5

다음페이지